Clinical Usefulness of Endometrial Aspiration Cytology and CA-125 in the Detection of Fallopian Tube Carcinoma

1997 ◽  
Vol 41 (5) ◽  
pp. 1445-1450 ◽  
Author(s):  
Nobuhiro Takeshima ◽  
Yasuo Hirai ◽  
Kazuhiro Yamauchi ◽  
Katsuhiko Hasumi
Keyword(s):  
Fallopian Tube ◽  
Clinical Usefulness ◽  
Ca 125 ◽  
Fallopian Tube Carcinoma ◽  
Aspiration Cytology

scholarly journals Serum CA 125 and Fallopian Tube Carcinoma

2001 ◽  
Vol 21 (1-2) ◽  
pp. 130-130
Author(s):  
Zouhair O. Amarin ◽  
H. Jamal
Keyword(s):  
Fallopian Tube ◽  
Ca 125 ◽  
Fallopian Tube Carcinoma

Preoperative and postoperative CA-125 serum levels in primary Fallopian tube carcinoma

1994 ◽  
Vol 255 (2) ◽  
pp. 65-68 ◽  
Author(s):  
A. C. Rosen ◽  
M. Klein ◽  
H. R. Rosen ◽  
A. H. Graf ◽  
M. Lahousen ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Serum Levels ◽  
Ca 125 ◽  
Fallopian Tube Carcinoma ◽  
Primary Fallopian Tube Carcinoma

Preoperative and postoperative CA-125 serum levels in primary Fallopian tube carcinoma

1994 ◽  
Vol 255 (2) ◽  
pp. 65-68 ◽  
Author(s):  
A. C. Rosen ◽  
M. Klein ◽  
H. R. Rosen ◽  
A. H. Graf ◽  
M. Lahousen ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Serum Levels ◽  
Ca 125 ◽  
Fallopian Tube Carcinoma ◽  
Primary Fallopian Tube Carcinoma

scholarly journals Primary Fallopian Tube Carcinoma: A Case Report and Literature Review

2017 ◽  
Vol 5 (3) ◽  
pp. 344-348 ◽  
Author(s):  
Meral Rexhepi ◽  
Elizabeta Trajkovska ◽  
Hysni Ismaili ◽  
Florin Besimi ◽  
Nagip Rufati
Keyword(s):  
Fallopian Tube ◽  
Female Genital Tract ◽  
Lower Abdominal Pain ◽  
Ca 125 ◽  
Histopathological Diagnosis ◽  
Fallopian Tube Carcinoma ◽  
Rare Tumour ◽  
Initial Surgery ◽  
Primary Fallopian Tube Carcinoma ◽  
The Right

BACKGROUND: Primary fallopian tube carcinoma (PFTC) is a rare tumour of the female genital tract with an incidence of 0.1-1.8% of all genital malignancies, and it is very difficult to diagnose preoperatively, because of its non-specific symptomatology. In most cases, it is an intraoperative finding or a histopathological diagnosis. It is a tumour that histologically and clinically resembles epithelial ovarian cancer.CASE PRESENTATION: We are reporting a case of a 62-year-old, postmenopausal women with primary fallopian tube carcinoma of the right fallopian tube in stage IA. The patient has lower abdominal pain, watery vaginal discharge and repeated episodes of bleeding from the vagina. The clinical and radiological findings suggested a right adnexal tumour with elevated CA-125 levels. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and peritoneal washing were performed. Pathologic confirmation of primary serous cystadenocarcinoma of the right fallopian tube was made. Peritoneal washings were negative for malignancy. FIGO stage was considered as IA, and the patient received no courses of chemotherapy and postoperative radiation because she refused it. Ten months after initial surgery, the patient is alive and in good condition.CONCLUSION: Cytoreduction surgery followed by adequate cycles of chemotherapy is an important strategy to improve patients’ prognosis.

Preoperative diagnosis of fallopian tube carcinoma by transvaginal sonography and CA-125

1990 ◽  
Vol 37 (1) ◽  
pp. 129-131 ◽  
Author(s):  
Shahar Kol ◽  
David Gal ◽  
Michael Friedman ◽  
Eitan Paldi
Keyword(s):  
Fallopian Tube ◽  
Preoperative Diagnosis ◽  
Ca 125 ◽  
Transvaginal Sonography ◽  
Fallopian Tube Carcinoma

scholarly journals Primary fallopian tube carcinoma

2009 ◽  
Vol 62 (1-2) ◽  
pp. 31-36 ◽  
Author(s):  
Ljiljana Mladenovic-Segedi
Keyword(s):  
Ovarian Carcinoma ◽  
Fallopian Tube ◽  
Female Genital Tract ◽  
Total Abdominal Hysterectomy ◽  
Cystic Mass ◽  
Common Finding ◽  
Ca 125 ◽  
Fallopian Tube Carcinoma ◽  
Brca1 And Brca2 ◽  
Primary Fallopian Tube Carcinoma

Introduction. Primary fallopian tube carcinoma is extremely rare, making 0.3-1.6% of all female genital tract malignancies. Although the etymology of this tumor is unknown, it is suggested to be associated with chronic tubal inflammation, infertility, tuberculous salpingitis and tubal endometriosis. High parity is considered to be protective. Cytogenetic studies show the disease to be associated with over expression of p53, HER2/neu and c-myb. There is also some evidence that BRCA1 and BRCA2 mutations have a role in umorogeneis. Clinical features. The most prevailing symptoms with fallopian tube carcinoma are abdominal pain, abnormal vaginal discharge/bleeding and the most common finding is an adnexal mass. In many patients, fallopian tube carcinoma is asymptomatic. Diagnosis. Due to its rarity, preoperative diagnosis of primary fallopian tube carcinoma is rarely made. It is usually misdiagnosed as ovarian carcinoma, tuboovarian abscess or ectopic pregnancy. Sonographic features of the tumor are non-specific and include the presence of a fluid-filled adnexal structure with a significant solid component, a sausage-shaped mass, a cystic mass with papillary projections within, a cystic mass with cog wheel appearance and an ovoid-shaped structure containing an incomplete separation and a highly vascular solid nodule. More than 80% of patients have elevated pretreatment serum CA-125 levels, which is useful in follow-up after the definite treatment. Treatment. The treatment approach is similar to that of ovarian carcinoma, and includes total abdominal hysterectomy and bilateral salpingo-oophorectomy. Staging is followed with chemotherapy.

Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma

2005 ◽  
Vol 15 (4) ◽  
pp. 612-617 ◽  
Author(s):  
B. Piura ◽  
A. Rabinovich
Keyword(s):  
Partial Response ◽  
Fallopian Tube ◽  
Dose Intensity ◽  
Complete Response ◽  
Ca 125 ◽  
Hematologic Toxicity ◽  
Fallopian Tube Carcinoma ◽  
Heavily Pretreated ◽  
Pretreated Patients ◽  
Grade 3

Topotecan has demonstrated antitumor activity in heavily pretreated patients with ovarian carcinoma. This report examines the activity and toxicity of topotecan in 29 heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Topotecan 1.5 mg/m2 was administered intravenously on days 1–5, every 21 days. It was second-line chemotherapy in 6 (20.7%) patients, third-line in 15 (51.7%), fourth-line in 4 (13.8%), fifth-line in 3 (10.3%), and seventh-line in 1 (3.4%). Median dose intensity was 1.667 mg/m2/week, and median relative dose intensity was 0.67. Disease complete response was observed in 5 (17.2%) patients, partial response in 1 (3.4%), stable disease in 12 (41.4%), and progressive disease in 11 (37.9%). CA-125 complete response was observed in 3 (10.3%) patients, partial response in 11 (37.9%), stable level in 5 (17.2%), and progressive level in 9 (31%), and no data were available in 1 (3.4%) patient. Toxicity was mainly hematologic: grade 3–4 neutropenia was observed in 20 (69%) patients, grade 3–4 leukopenia in 12 (41.4%), grade 3–4 thrombocytopenia in 9 (31%), and grade 3–4 anemia in 2 (6.9%). It is concluded that topotecan has considerable activity and noncumulative hematologic toxicity in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.

Preoperative Sonographic Diagnosis of Primary Fallopian Tube Carcinoma

2002 ◽  
Vol 21 (10) ◽  
pp. 1171-1173 ◽  
Author(s):  
Jimmy H. F. Yuen ◽  
Grace C. Y. Wong ◽  
Christina H. L. Lam
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Carcinoma ◽  
Sonographic Diagnosis ◽  
Primary Fallopian Tube Carcinoma
Sign in / Sign up

Export Citation Format

Share Document